Monte Carlo Simulation Analysis of Variant Burden Prompts Potential Oligogenic Interactions
Pata, V.; Marandi, M.; Huik, J. M.; Ounap, K.; Pajusalu, S.
Show abstract
BackgroundA large fraction of patients with suspected rare genetic disorders remain undiagnosed, suggesting that complex inheritance patterns, which are poorly detected by standard monogenic tests, may be a key factor. MethodsWe developed a computational framework that uses Monte Carlo simulations on summary-level allele counts to test for pathway-level burden enrichment. This approach was applied to a cohort of 639 neuromuscular disease (NMD) patients and 9,059 controls from the Tartu University Hospital (2015-2023) as proof of concept and compared with standard burden testing. ResultsWhile standard per-gene Z-tests failed to yield genome-wide significant results, our simulation framework identified a nominal enrichment of rare, moderate-impact variants within a predefined set of NMD-associated genes (Bonferroni-corrected empirical p = 0.02). Exploratory analysis of the most significantly burdened gene sets revealed frequent co-occurrence of CAPN3 with other critical NMD genes, including CLCN1, GFPT1, and MYOT. ConclusionOur findings suggest a potential oligogenic model in NMD, where variants in a hub gene like CAPN3 may interact with other rare variants to contribute to disease. This Monte Carlo simulation framework needs further validation but demonstrates that this framework may be a useful tool for hypothesis generation in complex genetic disorders. FundingEstonian Research Council grants PSG774 and PRG2040. Availabilitypublicly available under CC BY-NC-SA 4.0 licence at https://github.com/OligoGeneticDiseases/gen-toolbox
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Extracting and calibrating evidence of variant pathogenicity from population biobank data 94%
- MRSD: a novel quantitative approach for assessing suitability of RNA-seq in the clinical investigation of mis-splicing in Mendelian disease 94%
- Genome Sequencing and Comprehensive Rare Variant Analysis of 465 Families with Neurodevelopmental Disorders 93%
Similar papers in this journal
- Evaluating Genome Sequencing Strategies: Trio, Singleton, and Standard Testing in Rare Disease Diagnosis 94%
- Systematic analysis of genetic and phenotypic characteristics reveals antisense oligonucleotide therapy potential for one-third of neurodevelopmental disorders 94%
- Clustering of predicted loss-of-function variants in genes linked with monogenic disease can explain incomplete penetrance 94%
Similar papers in this journal
- A gene pathogenicity tool 'GenePy' identifies missed biallelic diagnoses in the 100,000 Genomes Project 95%
- The Importance of Automation in Genetic Diagnosis: Lessons from Analyzing an Inherited Retinal Degeneration Cohort with the Mendelian Analysis Toolkit (MATK) 94%
- Diagnosing missed cases of spinal muscular atrophy in genome, exome, and panel sequencing datasets 94%
Similar papers in this journal
- Whole genome sequencing of ‘mutation-negative’ individuals with Cornelia de Lange Syndrome 93%
- Matching whole genomes to rare genetic disorders: Identification of potential causative variants using phenotype-weighted knowledge in the CAGI SickKids5 clinical genomes challenge 93%
- GeneBreaker: Variant simulation to improve the diagnosis of Mendelian rare genetic diseases 93%
Similar papers in this journal
- Efficient and Flexible Integration of Variant Characteristics in Rare Variant Association Studies Using Integrated Nested Laplace Approximation 93%
- Differential allelic representation (DAR) identifies candidate eQTLs and improves transcriptome analysis 93%
- High-throughput Interpretation of Killer-cell Immunoglobulin-like Receptor Short-read Sequencing Data with PING 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.